<DOC>
	<DOCNO>NCT01510626</DOCNO>
	<brief_summary>The long-term goal investigator study develop good safer treatment , potentially cure patient single multiple food allergy . The investigator hypothesize application protocol allow patient severe single multiple food allergy safely rapidly desensitize .</brief_summary>
	<brief_title>Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study Single Center</brief_title>
	<detailed_description />
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Food Hypersensitivity</mesh_term>
	<mesh_term>Immune System Diseases</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Moderate severe peanut and/or egg and/or milk and/or tree nut and/or seed allergic subject age 4 55 year old . Sensitivity food allergen document positive skin prick test result allergenspecific ImmunoCAP IgE level , 7 kU/L low limit eligibility . No absolute contraindication know . However , risk serious systemic anaphylactic reaction food allergen suggest number preexist condition consider relative contraindication . Among condition acute infection , autoimmune disease , severe cardiac disease , treatment betaadrenergic antagonistic drug ( betablockers ) . Subjects total IgE screening &gt; 2,000 kU/L Previous reaction omalizumab Subjects history severe anaphylaxis food allergen desensitize study require intubation admission ICU , frequent allergic nonallergic urticaria , history consistent poorly control persistent asthma .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Multiple food allergy</keyword>
</DOC>